The OXYLINK is a smart device that provides patients suffering from respiratory insufficiency almost immediate relief. Patiets receive a safe and more effective treatment without the complications associated with mechanical ventilation. The patient is treated while awake without the need for being placed into a medically induced coma and without neuromuscular blocking agents. InSense has performed several studies including on a 30kg swine, where oxygen levels were increased and carbon dioxide levels were reduced. The company is undergoing a Series A Round of $3.5m, with an FDA IDE submission within 12 months. Based on U.S FDA legal and consulting companies, InSense will attain FDA Certification within 36 months, fast lane De Novo Program.